Curis Inc.

1.06-0.0500-4.50%Vol 804.68K1Y Perf -84.92%
Aug 16th, 2022 16:00 DELAYED
BID1.06 ASK1.10
Open1.11 Previous Close1.11
Pre-Market- After-Market1.09
 - -  0.03 2.83%
Target Price
10.00 
Analyst Rating
Moderate Buy 1.67
Potential %
843.40 
Finscreener Ranking
★★★★     52.52
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★     52.19
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★★★     56.89
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
4.32 
Earnings Rating
Sell
Market Cap97.32M 
Earnings Date
4th Aug 2022
Alpha0.03 Standard Deviation0.66
Beta2.83 

Today's Price Range

1.051.12

52W Range

0.70009.04

5 Year PE Ratio Range

-6.60-2.90

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
1.92%
1 Month
-5.36%
3 Months
22.76%
6 Months
-67.68%
1 Year
-84.92%
3 Years
-47.26%
5 Years
-87.82%
10 Years
-95.05%

TickerPriceChg.Chg.%
CRIS1.06-0.0500-4.50
AAPL173.03-0.1600-0.09
GOOG122.51-0.3700-0.30
MSFT292.71-0.7600-0.26
XOM91.46-0.8600-0.93
WFC46.060.31000.68
JNJ167.571.48000.89
FB196.640.99000.51
GE81.071.26001.58
JPM123.631.17000.96
 
ProfitabilityValueIndustryS&P 500US Markets
96.00
-493.80
-492.30
-376.60
-
RevenueValueIndustryS&P 500US Markets
10.62M
0.12
2.88
4.09
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.17-0.170.00
Q01 2022-0.17-0.18-5.88
Q04 2021-0.13-0.15-15.38
Q03 2021-0.13-0.127.69
Q02 2021-0.11-0.12-9.09
Q01 2021-0.09-0.11-22.22
Q04 2020-0.07-0.11-57.14
Q03 2020--0.11-
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.17-6.25Negative
9/2022 QR-0.17-6.25Negative
12/2022 FY-0.67-6.35Negative
12/2023 FY-0.607.69Positive
Next Report Date-
Estimated EPS Next Report-0.17
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume804.68K
Shares Outstanding91.81K
Shares Float91.39M
Trades Count2.82K
Dollar Volume864.01K
Avg. Volume2.05M
Avg. Weekly Volume1.53M
Avg. Monthly Volume1.69M
Avg. Quarterly Volume2.94M

Curis Inc. (NASDAQ: CRIS) stock closed at 1.06 per share at the end of the most recent trading day (a -4.5% change compared to the prior day closing price) with a volume of 804.68K shares and market capitalization of 97.32M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 28 people. Curis Inc. CEO is James E. Dentzer.

The one-year performance of Curis Inc. stock is -84.92%, while year-to-date (YTD) performance is -77.73%. CRIS stock has a five-year performance of -87.82%. Its 52-week range is between 0.7 and 9.04, which gives CRIS stock a 52-week price range ratio of 4.32%

Curis Inc. currently has a PE ratio of -1.90, a price-to-book (PB) ratio of 1.70, a price-to-sale (PS) ratio of 9.59, a price to cashflow ratio of 36.40, a PEG ratio of 2.32, a ROA of -36.59%, a ROC of -57.30% and a ROE of -65.00%. The company’s profit margin is -%, its EBITDA margin is -492.30%, and its revenue ttm is $10.62 Million , which makes it $0.12 revenue per share.

Of the last four earnings reports from Curis Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.17 for the next earnings report. Curis Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Curis Inc. is Moderate Buy (1.67), with a target price of $10, which is +843.40% compared to the current price. The earnings rating for Curis Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Curis Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Curis Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.82, ATR14 : 0.11, CCI20 : 42.95, Chaikin Money Flow : -0.09, MACD : 0.00, Money Flow Index : 47.94, ROC : 9.90, RSI : 39.38, STOCH (14,3) : 72.22, STOCH RSI : 0.86, UO : 55.20, Williams %R : -27.78), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Curis Inc. in the last 12-months were: James E. Dentzer (Sold 5 500 shares of value $17 150 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
2 (66.67 %)
3 (75.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (33.33 %)
1 (33.33 %)
1 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Moderate Buy
1.67
Strong Buy
1.50

Curis Inc.

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

CEO: James E. Dentzer

Telephone: +1 617 503-6500

Address: 4 Maguire Road, Lexington 02421, MA, US

Number of employees: 28

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

58%42%

Bearish Bullish

63%37%

TipRanks News for CRIS

Fri, 07 Jan 2022 16:25 GMT Curis (CRIS) Gets a Buy Rating from B.Riley Financial

- TipRanks. All rights reserved.

News

Stocktwits